Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sarcosine + selective serotonin reuptake inhibitor
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sarcosine + selective serotonin reuptake inhibitor (SSRI) is a combination therapy involving the co-administration of sarcosine (N-methylglycine), an endogenous amino acid and glycine transporter-1 (GlyT-1) inhibitor, with an SSRI, a class of antidepressants that inhibit the neuronal reuptake of serotonin. Sarcosine acts by increasing synaptic glycine levels and enhancing N-methyl-D-aspartate receptor (NMDA receptor) function, thereby modulating glutamatergic neurotransmission. SSRIs increase serotonergic neurotransmission by blocking the serotonin transporter. This combination has been studied as an add-on treatment for major depressive disorder (MDD), schizophrenia, obsessive-compulsive disorder (OCD), and other neuropsychiatric conditions to improve efficacy over monotherapy. Clinical trials have shown that adding sarcosine to SSRIs can result in greater reductions in depressive symptoms and higher response/remission rates compared to SSRIs alone[1]. The combination may also be beneficial in treatment-resistant cases but requires careful dose adjustment due to potential synergistic effects on serotonergic transmission[5].
- Other names
- sarcosine + SSRIsarcosine plus selective serotonin reuptake inhibitor
02
Targets
SLC6A9 (Glycine transporter type 1)SERT (Sodium-dependent serotonin transporter)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on sarcosine + selective serotonin reuptake inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sarcosine + selective serotonin reuptake inhibitor.